TY  - JOUR
AU  - Baddley, J W
AU  - Cantini, F
AU  - Goletti, D
AU  - Gomez-Reino, J J
AU  - Mylonakis, E
AU  - San-Juan, R
AU  - Fernandez-Ruiz, M
AU  - Torre-Cisneros, J
PY  - 2017
DO  - 10.1016/j.cmi.2017.12.025
UR  - http://hdl.handle.net/10668/12153
T2  - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
AB  - The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies. To review, from an Infectious Diseases perspective, the safety profile of agents...
LA  - en
PB  - Elsevier
KW  - Adalimumab
KW  - Certolizumab pegol
KW  - Etanercept
KW  - Golimumab
KW  - Infection
KW  - Infliximab
KW  - Prevention
KW  - Tuberculosis
KW  - Tumour necrosis factor-α
KW  - Adalimumab
KW  - Anti-inflammatory agents
KW  - Antibodies, monoclonal
KW  - Biological therapy
KW  - Clinical trials as topic
KW  - Communicable disease control
KW  - Communicabled iseases
KW  - Etanercept
KW  - Hepatitis B, chronic
KW  - Humans
KW  - Immunocompromised host
KW  - Immunologic factors
KW  - Infliximab
KW  - Latent tuberculosis
KW  - Molecular targeted therapy
KW  - Tumor necrosis factor-alpha
KW  - Viral vaccines
TI  - ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).
TY  - research article
VL  - 24 Suppl 2
ER  -